Industry News
Biotechnology Industry News
Merck & Co.’s PCSK9-targeted…
Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions similar to those observed with existing injectables.
AnaptysBio has abandoned plans to…
AnaptysBio has abandoned plans to develop rosnilimab for ulcerative colitis after the PD-1 agonist flunked a phase 2 study.
In a licensing deal unveiled…
In a licensing deal unveiled Monday, Lyell Immunopharma is handing over $40 million in cash and almost 2 million of its shares to secure rights to a phase 1-stage CAR-T cell therapy for colorectal cancer.
Roche has reported wins for its…
Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 multiple sclerosis trials. One victory was based on the finding that the candidate was non-inferior to Ocrevus, despite the company
AstraZeneca’s aldosterone synthase…
AstraZeneca's aldosterone synthase inhibitor baxdrostat reduced blood pressure by 14 mmHg over 12 weeks, the pharma has said in a first look at the data from a key phase 3 win.
The FDA has put a clinical hold on…
The FDA has put a clinical hold on a Tenaya Therapeutics gene therapy study while the biotech works to standardize activities related to the immunosuppression regimen across trial sites.
Eli Lilly has penned a research…
Eli Lilly has penned a research pact worth $1.2 billion in biobucks with SanegeneBio to help pinpoint cardiometabolic RNAi medicines at the correct tissues.
After a chaotic and fierce bidding…
After a chaotic and fierce bidding clash that only burst out into public view a little more than a week ago, Pfizer has prevailed in its pursuit of obesity biotech Metsera.
MeiraGTx is cashing in on a gene…
MeiraGTx is cashing in on a gene therapy that restored vision to 11 children who were born legally blind, licensing the program to Eli Lilly in a deal potentially worth more than $475 million.
Amid Novo Nordisk and Pfizer’s…
Amid Novo Nordisk and Pfizer’s whiplash bidding war for obesity biotech Metsera, Novo’s CEO has, quite literally, told its rival to put its money where its mouth is.
Sana Biotechnology, CAMP4…
Sana Biotechnology, CAMP4 Therapeutics and Crinetics Pharmaceuticals have all used the third quarter to refocus their pipelines on the most promising candidates.
The patient who was hospitalized…
The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. Both phase 3 studies of the candidate remain on hold as the biotech works to understand liver-related events seen in the
Twelve years after establishing…
Twelve years after establishing TechBio company Recursion, co-founder and CEO Chris Gibson, Ph.D., will soon step down to let Chief R&D and Commercial Officer Najat Khan, Ph.D., take the wheel.
Biotech firm prepares for pivotal…
Biotech firm prepares for pivotal trials as it positions Teverelix to address unmet needs in prostate cancer, urology and beyond.
The FDA has released the second…
The FDA has released the second batch of recipients for the new "national priority voucher" program, with executives for two of the beneficiaries appearing in the Oval Office with President Donald Trump Nov. 6.
More than a year and a half into…
More than a year and a half into Cullinan Therapeutics’ pivot from a CD19-focused oncology company to a hybrid autoimmune player, the biotech is parting ways with a pair of cancer programs.
Discover how these trailblazers…
Discover how these trailblazers are accelerating breakthroughs, forging impactful partnerships, and redefining what’s possible in life sciences. Access the exclusive interviews below to get inspired and stay ahead of the curve.
Axsome Therapeutics has wrapped…
Axsome Therapeutics has wrapped its hands around an epilepsy candidate from AstraZeneca through an acquisition of Avenue Therapeutics' subsidiary Baergic Bio, in a deal potentially worth more than $83 million.
UroGen is handing an anti-CTLA-4…
UroGen is handing an anti-CTLA-4 antibody back to Agenus after concluding that phase 1 data for the bladder cancer drug didn’t reach the benchmark for further development.
First, the phase 3 trial of…
First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. Now, the study has to head back for a second season in the Northern Hemisphere after failing to find enough